|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0030705,
umls-concept:C0205412,
umls-concept:C0205460,
umls-concept:C0242708,
umls-concept:C0439852,
umls-concept:C0450442,
umls-concept:C0871261,
umls-concept:C1609165,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707455,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-5-25
|
|
pubmed:abstractText |
To compare the patterns of American College of Rheumatology (ACR) response between tocilizumab and other biologic agents in patients with rheumatoid arthritis who have inadequate response to disease-modifying antirheumatic drugs (DMARD-IR).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1532-866X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
425-41
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20223500-Antibodies, Monoclonal,
pubmed-meshheading:20223500-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20223500-Antirheumatic Agents,
pubmed-meshheading:20223500-Arthritis, Rheumatoid,
pubmed-meshheading:20223500-Double-Blind Method,
pubmed-meshheading:20223500-Humans,
pubmed-meshheading:20223500-Immunosuppressive Agents,
pubmed-meshheading:20223500-Randomized Controlled Trials as Topic,
pubmed-meshheading:20223500-Treatment Failure,
pubmed-meshheading:20223500-Treatment Outcome,
pubmed-meshheading:20223500-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.
|
|
pubmed:affiliation |
Mapi Values, Houten, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Review,
Research Support, Non-U.S. Gov't
|
